Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-ii-associated wilms tumors

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7635-7644

  Vuononvirta, Raisa ^a   Sebire, Neil J ^b   Dallosso, Anthony R ^e   Reis Filho, Jorge S ^c   Williams, Richard D ^a   Mackay, Alan ^c   Fenwick, Kerry ^c   Grigoriadis, Anita ^c,d   Ashworth, Alan ^c   Pritchard Jones, Kathy ^a   Brown, Keith W ^e   Vujanic, Gordan M ^f   Jones, Chris ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; IGF2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME 11P; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EPIGENETICS; GENE EXPRESSION; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CYST; NEPHROBLASTOMA; PERILOBAR NEPHROGENIC RESTS; PRIORITY JOURNAL; DNA METHYLATION; GENE DOSAGE; GENETICS; HETEROZYGOSITY LOSS; KIDNEY TUMOR; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PRECANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BASE SEQUENCE; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; GENE DOSAGE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WILMS TUMOR;

EID: 59449110723     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1620     Document Type: Article

References (36)

1. Schedl A. Renal abnormalities and their developmental origin. Nat Rev Genet 2007;8:791-802.
2. Rivera MN, Haber DA. Wilms tumour: connecting tu-morigenesis andorgan development in the kidney. Nat Rev Cancer 2005;5:699-712.
3. Beckwith JB, Kiviat NB, BonadioJF. Nephrogenic rests, nephroblastomatosis, andthe pathogenesis of Wilms tumor. Pediatr Pathol 1990;10:1-36.
4. Fukuzawa R, Reeve AE. Molecular pathology andep-idemiology of nephrogenic rests and Wilms tumors. J Pediatr Hematol Oncol 2007;29:589-94.
5. Park S, BernardA, Bove KE, et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms tumour. Nat Genet1993;5:363-7.
6. Charles AK, Brown KW, Berry PJ. Microdissecting the genetic events in nephrogenic rests and Wilms tumor development. Am J Pathol 1998;153:991-1000.
7. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature1993;362:747-9.
8. Fukuzawa R, Breslow NE, Morison IM, et al. Epige-netic differences between Wilms tumours in White andEast-Asian children. Lancet 2004;363:446-51.
9. Ohlsson R, Cui H, He L, et al. Mosaic allelic insulinlike growth factor 2 expression patterns reveal a link between Wilms tumorigenesis and epigenetic heterogeneity. Cancer Res1999;59:3889-92.
10. Bjornsson HT, Brown LJ, Fallin MD, et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 2007;99:1270-3.
11. Schumacher V, Schuhen S, Sonner S, et al. Two molecular subgroups of Wilms tumors with or without WT1mutations. Clin Cancer Res 2003;9:2005-14.
12. Ravenel JD, Broman KW, Perlman EJ, et al. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001;93:1698-703.
13. Natrajan R, Reis-Filho JS, Little SE, et al. Blastemal expression of type I insulin-like growth factor receptor in Wilms tumors is driven by increased copy number and correlates with relapse. Cancer Res 2006;66:11148-55.
14. Natrajan R,Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains andlosses associatedwith relapse. J Pathol 2006;210:49-58.
15. Little SE,Vuononvirta R, Reis-Filho JS, et al. Array CGH using whole genome amplification of fresh-frozen andformalin-fixed, paraffin-embedded tumor DNA. Genomics 2006;87:298-306.
16. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
17. WaldmanFM,DeVriesS,ChewKL,MooreDHII, Kerlikowske K, Ljung BM. Chromosomal alterations in ductal carcinomas in situ andtheir in situ recurrences. J Natl Cancer Inst 2000;92:313-20.
18. Natrajan R, Louhelainen J, Williams S, Laye J, Knowles MA. High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63:7657-62.
19. Watanabe N, Nakadate H, Haruta M, et al. Association of11q loss, trisomy12, andpossible16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 2006;45:592-601.
20. Breslow N, Olshan A, Beckwith JB, Green DM. Epidemiology of Wilms tumor. Med Pediatr Oncol 1993;21:172-81.
21. Breslow NE, Beckwith JB, Perlman EJ, Reeve AE. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilmstumor. Pediatr Blood Cancer 2006;47:260-7.
22. Bove KE, McAdams AJ. The nephroblastomatosis complex andits relationship to Wilms tumor: a clinico-pathologic treatise. Perspect Pediatr Pathol 1976;3:185-223.
23. Beckwith JB. Nephrogenic rests andthepathogen-esis of Wilms tumor: developmental and clinical considerations. Am J Med Genet1998;79:268-73.
24. Fukuzawa R, Heathcott RW, More HE, Reeve AE. Sequential WT1 andCTNNB1 mutations andaltera-tions of β-catenin localisation in intralobar nephro-genic rests andassociatedWilms tumours: two case studies. J Clin Pathol 2007;60:1013-6.
25. Ruteshouser EC, Hendrickson BW, Colella S, Krahe R, Pinto L, Huff V. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 2005;43:172-80.
26. Mummert SK, Lobanenkov VA, Feinberg AP. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosomes Cancer 2005;43:155-61.
27. Yuan E, Li CM,Yamashiro DJ, et al. Genomic profiling maps loss of heterozygosity anddefines the timing and stage dependence of epigenetic andgenetic events in Wilms tumors. Mol Cancer Res 2005;3:493-502.
28. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplas-tic Wilms tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7: 91-7.
29. Gow KW, Murphy JJ. Cytogenetic andhistologic findings in Wilms tumor. J Pediatr Surg 2002;37: 823-7.
30. Bove KE, Lewis C, Debrosse BK. Proliferation and maturation indices in nephrogenic rests and Wilms tumor; the emergence of heterogeneity from dormant nodular renal blastema. Pediatr Pathol Lab Med 1995; 15:223-44.
31. Major MB, Camp ND, Berndt JD, et al.Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science2007;316:1043-6.
32. Lee YI, Kim SJ. Transcriptional repression of human insulin-like growth factor-II P4 promoter by Wilms tumor suppressor WT1. DNA Cell Biol 1996; 15:99-104.
33. Werner H, Re GG, DrummondI A, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation ofIGF1R promoter activity by theWT1Wilmstu-mor gene product. Proc Natl Acad Sci U SA1993;90:5828-32.
34. Chen J,Wu A, Sun H, et al. Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and h-catenin. J Biol Chem 2005;280:29912-20.
35. Bendall SC, Stewart MH, MenendezP, et al. IGF and
36. FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 2007; 448:1015-21.